Dyne Therapeutics, Inc. (DYN) on Monday reported positive topline results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen) in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The company also released new long-term data from the trial's open-label extension and long-term extension phases.
The REC achieved its primary endpoint, showing a statistically significant increase in muscle content-adjusted dystrophin expression to 5.46% of normal at six months. Dyne said functional improvements were observed across multiple measures at six months, and lung function was maintained. Long-term data showed sustained functional benefit across all assessed endpoints through 24 months.
Dyne said it plans to submit a Biologics License Application for Z-Rostudirsen for U.S. accelerated approval in the second quarter of 2026 and will launch a global Phase 3 study of z-rostudirsen in the same period. Assuming priority review, the company expects a potential U.S. launch in the first quarter of 2027.
Dyne Therapeutics shares closed Friday's trading at $20.28, up 1.79%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.